BISOPRESS

Bisoprolol Fumarate USP

COMPOSITION

Bisopress 2.5 Tablet: Each film coated tablet contains Bisoprolol Fumarate USP 2.5 mg.
Bisopress 5 Tablet: Each film coated tablet contains Bisoprolol Fumarate USP 5 mg.

PHARMACOLOGY

Bisoprolol Fumarate is the most selective ß1 blocker. It displays highest level of affinity for the ß1 receptor than any other beta-blocker available up to now. Selectively blocks ß1 adrenergic receptor in the heart and vascular smooth muscle and reduces heart rate and cardiac output resulting in decrease of arterial hypertension. Lipid metabolism can be adversely affected by ß-blockers, in patients with non-seletive ß1-blocker, but Bisoprolol does not cause any change in the cholesterol fraction including the cardioprotective HDL-cholesterol, in long-term therapy.

INDICATION

- Hypertension
- Angina
- Moderate to severe heart failure

DOSAGE AND ADMINISTRATION

Hypertension: The dose of Bisoprolol must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
Angina: Usually 10 mg once daily (5 mg may be adequate in some patients) max 20 mg daily.
Heart Failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then- 7.5 mg once daily for 4 weeks, then 10 mg once daily maximum 10 mg daily.

CONTRAINDICATION

In patients with cardiogenic shock, overt heart failure, second or third degree A-V block, right ventricular failure secondary to pulmonary hypertension and sinus bradycardia.

WARNING AND PRECAUTION

Monitoring of renal, hepatic and hematopoietic function should be performed at regular intervals during long-term treatment with Bisoprolol.

SIDE EFFECTS

Gastro-intestinal disturbances, bradycardia, hypotension, headache, fatigue, sleep disturbances, dizziness, vertigo, thrombocytopenia, visual disturbances, alopecia may be occurred.

USE IN PREGNANCY AND LACTATION

Use in pregnancy: The safety of Bisoprolol during pregnancy has not been established.
Use in lactation: No data is available for lactation.

USE IN CHILDREN AND ADOLESCENTS

The safety and efficacy of Bisoprolol in children & adolescent patients have not been established.

DRUG INTERACTION

Bisoprolol should not be combined with other ß-blocking agents.

OVERDOSAGE

If overdose occurs, Bisoprolol therapy should be stopped and supportive and symptomatic treatment should be provided. Bisoprolol Fumarate is not dialyzable.

STORAGE

Store below 30^{O}C temperature in a cool & dry place. Protect from light & moisture. Keep out of the reach of children.

HOW SUPPLIED

Bisopress 2.5 Tablet: Each box contains 30 tablets in Alu-Alu blister pack.
Bisopress 5 Tablet: Each box contains 30 tablets in Alu-Alu blister pack.

02063/00

NIPRO JMI Pharma

Manufactured by:
NIPRO JMI Pharma Ltd.
Chauddagram, Cumilla, Bangladesh.